How do different ADAM10 isoforms contribute differentially to non-amyloidogenic APP processing?

OPEN

While the abstract emphasizes ADAM10's role in non-amyloidogenic APP processing and proposes standardized isoform nomenclature, it doesn't clarify functional differences between isoforms. This knowledge is essential for isoform-specific therapeutic targeting in AD. Gap type: open_question Source paper: ADAM10 isoforms: Optimizing usage of antibodies based on protein regulation, structural features, biological activity and clinical relevance to Alzheimer's disease. (2024, Ageing research reviews, PMID:39173916)

Priority: 0.77 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: How do different ADAM10 isoforms contribute differentially to non-amyloidogenic APP processing? is a 0.77 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How do different ADAM10 isoforms contribute differentially to non-amyloidogenic APP processing? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

Resolution

Mechanistic Families

Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (16)

INFLAMMATION→APPALZHEIMER→APPNEURODEGENERATION→APPAPP→ApoptosisAPP→Alzheimer

▸ Show 11 more

AMYLOID→APPAPP→NeurodegenerationAPP→NeuroinflammationAPP→DementiaAPP→InflammationAPP→AutophagyAPP→NEUROINFLAMMATIONAPP/PS1→APPGENES→APPAPP→AlsAPOPTOSIS→APP

associated with (8)

APP→CORTEXAPOPTOSIS→APPAPP→TNFAPP→HIPPOCAMPUSAPP→DEMENTIA

▸ Show 3 more

APP→ASTROCYTESAPP→CancerAPP→BDNF

data in (7)

ADAM10→benchmark_ot_ad_answer_key:ADAM10benchmark_ot_ad_answer_key:APP→APPad_genetic_risk_loci:APP→APPbenchmark_ot_ad_answer_key:ADAM10→ADAM10ds-83b31ef18d49→APP

▸ Show 2 more

ds-83b31ef18d49→ADAM10ds-f50762b67605→APP

🕑 Activity Feed

✏ update on knowledge_gap by max_gmail 2026-04-12T14:41

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps

How do different ADAM10 isoforms contribute differentially to non-amyloidogenic APP processing?

Key Unanswered Questions

Key Researchers

Clinical Trials

Hypothesis Score Distribution

activates (16)

associated with (8)

data in (7)

expressed in (1)

expresses (1)

inhibits (5)

interacts with (1)

protects against (1)

provides data for (4)

regulates (2)

therapeutic target (3)

treats (1)